These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1006 related items for PubMed ID: 23652444

  • 21. Effects of Renin-Angiotensin-Aldosterone System Blockade in Patients with End-Stage Renal Disease.
    Slomka T, Lennon ES, Akbar H, Gosmanova EO, Bhattacharya SK, Oliphant CS, Khouzam RN.
    Am J Med Sci; 2016 Mar; 351(3):309-16. PubMed ID: 26992264
    [Abstract] [Full Text] [Related]

  • 22. Complete inhibition of the renin-angiotensin-aldosterone system; where do we stand?
    Chen SS, Seliger SL, Fried LF.
    Curr Opin Nephrol Hypertens; 2014 Sep; 23(5):449-55. PubMed ID: 25014549
    [Abstract] [Full Text] [Related]

  • 23. Inhibition of the renin-angiotensin-aldosterone system: how to obtain this.
    Pende A, Montecucco F.
    Curr Pharm Des; 2012 Sep; 18(7):950-1. PubMed ID: 22283769
    [No Abstract] [Full Text] [Related]

  • 24. Nephroprotective action of renin-angiotensin-aldosterone system blockade in chronic kidney disease patients: the landscape after ALTITUDE and VA NEPHRON-D trails.
    Rutkowski B, Tylicki L.
    J Ren Nutr; 2015 Mar; 25(2):194-200. PubMed ID: 25576239
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Arterial hypertension and proteinuria in pediatric chronic kidney disease.
    Simonetti GD, Bucher BS, Tschumi S, Lava SA, Bianchetti MG.
    Minerva Pediatr; 2012 Apr; 64(2):171-82. PubMed ID: 22495191
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway.
    Heerspink HJ.
    Adv Chronic Kidney Dis; 2011 Jul; 18(4):290-9. PubMed ID: 21782135
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials.
    Khatib R, Joseph P, Briel M, Yusuf S, Healey J.
    Int J Cardiol; 2013 Apr 30; 165(1):17-24. PubMed ID: 22421406
    [Abstract] [Full Text] [Related]

  • 40. Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE, Lyle PA, Tershakovec AM, Devereux RB, Oparil S, Dahlöf B, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Wedel H.
    Expert Opin Emerg Drugs; 2005 Nov 30; 10(4):729-45. PubMed ID: 16262560
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 51.